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Abstract 
The elongation factor-2 (eEF-2) is selectively phosphorylated by the eEF-2 kinase (calmodulin-dependent kinase III). This phosphorylation can 
be inhibited by calmodulin antagonists, such as CGS 9343B (IC,, = 4 PM). The novel protein kinase inhibitor rottlerin is shown to suppress eEF-2 
phosphorylation with an IC,, of 5.3 PM. By contrast, the eEF-2 kinase is rather resistant owards the potent but non-selective protein kinase inhibitor 
staurosporine (IC,, > 50 PM) and thus can be differentiated from most other protein kinases that are suppressed by staurosporine in the nM 
range. 
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1. Introduction 
The calmodulin-dependent kinase III (CaM-kinase 
III) appears to be highly specific for the elongation fac- 
tor-2 (eEF-2) and is therefore also termed eEF-2 kinase 
[l]. Conversely, eEF-2 is not significantly phosphoryl- 
ated by all the other protein kinases tested so far [l]. 
Phosphorylation of eEF-2 mainly occurs at two thre- 
onine residues (Thrs6 and Th?*), [2,3], resulting in an 
inactivation by reducing its affinity for the ribosome 
[4-71. Recently we have shown that phosphorylation of 
eEF-2 is reversed by a protein phosphatase 2A [8] and 
that the activity of this phosphatase [8,9] as well as the 
synthesis of eEF-2 [lo] are increased in mouse epidermis 
after treatment of the animals with the tumor-promoting 
phorbol ester TPA. Both TPA effects result in an in- 
crease of unphosphorylated, i.e. active eEF-2. Hormones 
and growth factors cause a temporary activation of eEF- 
2 kinase, resulting in a transient inhibition of elongation 
[I 1,121. This might allow newly synthesized mRNAs to 
enter the translation machinery [2]. In this context, it is 
intriguing that an increased phosphorylation of EF-2 
during mitosis correlates with a decreased rate of protein 
synthesis [13]. Thus, the eEF-2 kinase appears to play a 
crucial role in signal transduction. Very recently, Red- 
path and Proud [14] and Mitsui et al. [15] reported on 
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purification of the eEF-2 kinase (CaM-kinase III) from 
rabbit reticulocytes and rat pancreas. 
To our knowledge, besides CaM antagonists uch as 
cyclosporines [10,16,17], no other inhibitors of the eEF-2 
kinase have been found as yet. Here we show that the 
novel protein kinase inhibitor rottlerin effectively inhib- 
its this kinase. By contrast, the potent protein kinase 
inhibitor staurosporine fails to suppress eEF-2 kinase 
activity at concentrations sufficient to suppress most 
other protein kinases. 
2. Materials and methods 
2.1. Materials 
[y-‘*P]ATP (spec. act. 3000 Wmmol): DuPont-New England Nu- 
clear (Waltham, USA); staurosporine: Boehringer (Mannheim, Ger- 
many); K252a: Fluka Chemie AG, Neu-Ulm, Germany; rottlerin: Roth 
(Karlsruhe, Germany) calmodulin, quercetin, phloretin and genistein: 
Sigma, Mtinchen, Germany; chelerythrin: Calbiochem, Bad Soden, 
Germany; CGS 9343B and 686916 were kindly provided by Ciba- 
Geigy, Basel, Switzerland and Giidecke AG, Freiburg, Germany, re- 
spectively. 
2.2. Phosphorylation of eEF-2 
The cytosol of murine pancreas was prepared and proteins of pan- 
creas cytosol were phosphorylated with [j*P]ATP at 30°C for 4 min, 
essentially as previously described for murine epidermis [16]. 
One murine pancreas was homogenized in 3 ml of T&buffer (50 mM 
Tris-HCl, pH 7.5, 1 mM PMSF, 10 mM j?-mercaptoethanol) and the 
homogenate was centrifuged at 100,000 x g for 30 min. The supema- 
tant, termed cytosol, was used for the assay of eEF-2 phosphotylation. 
The assay contained 10 ~1 of cytosol, 72 ~1 of Tris-buffer, 10 ~1 of 
40 mM MgCl,, 2 ~1 of 10 mM CaCl, and 5 ~1 of a [32P]ATP/ATP mix 
(20 ~1 of 1.7 PM [‘*P]ATP (5 mCi/ml) + 80 ~1 of 750 PM ATP). 1 ~1 
of inhibitors or solvent as a control were added as indicated in the text. 
Phosphorylation was started by addition of the ATP mix. After incuba- 
tion at 30°C for 4 min the reaction was stopped by addition of 250 ~1 
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of 10% trichloroacetic acid. The pelleted proteins were dissolved in SDS 
sample buffer and applied to SDS polyacrylamide gel electrophoresis. 
The intensity of EF-2 phosphorylation was determined by densitomet- 
ric analysis of the autoradiograms. 
3. Results and discussion 
The elongation factor eEF-2 is the most prominent 
phosphoprotein in pancreas cytosol [ 1,9,16] and 
amounts to 1.7% of total cytosol protein [ 1,181. It is 
known to be phosphorylated in the cytosol specifically 
by an eEF-2 kinase (CaM-kinase III; [I]). Phosphoryla- 
tion of the 100 kDa protein eEF-2 in pancreas cytosol 
was strongly suppressed by either EGTA or CaM-antag- 
onists, such as CGS 9343B (see Fig. I, Table I), cy- 
closporines (see Table 1 and [10,16,17]) and FK-506 (see 
Table 1 and [19]) and thus was shown to be dependent 
on Ca” and CaM. Therefore, this cell-free system from 
pancreas was very well suited for the investigation of 
inhibitors of eEF-2 kinase. 
Pancreas cytosol was incubated with [32P]ATP in the 
presence or absence of various inhibitors at 30°C for 4 
min. In accordance with the report of Norman et al. [20] 
on a potent CaM-antagonistic action of CGS 9343B, we 
found that this compound suppressed the CaM-depend- 
ent phosphorylation of eEF-2 with an I&, of 4 ,uM (Fig. 
lb). Jefferson and Schulman have shown that sphingo- 
sine also acts as a calmodulin antagonist and inhibits 
eEF-2 phosphorylation with an I& of 20 ,uM [21]. 
Very recently, we found rottlerin, a compound isolated 
from Mallotus philippinensis [22], to act as a protein ki- 
nase inhibitor with some selectivity for protein kinase C 
type delta [23]. Rottlerin proved to be very effective also 
as an inhibitor of eEF-2 kinase (Fig. 2a). It suppressed 
the phosphorylation of eEF-2 with an IC,, of 5.3 yM. 
The inhibitory effect of rottlerin on eEF-2 kinase ap- 
peared to be due, at least in part, to a calmodulin-antag- 
onistic action, since addition of CaM to the assay caused 
Table 1 
Inhibition of eEF-2 kinase 
Inhibitor ICso 01M) 
CGS 9343 B 
Sphingosine 
Cyclosporine A 
Cyclosporine H 
FK-506 
Quercetin 
Phloretin 
H-9 
Chelerythrin 
Genistein 
Staurosporine 
Rottlerin 
“ref. [21]. 
bref. [lo] and unpublished ata. 
‘ref. [19] and unpublished ata. 
4 
20” 
lib 
41b 
50 
> 100 
> 100 
> 100 
> 100 
> 100 
> 50 
5.3 
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Fig. 1. Inhibition of eEF-2 phosphorylation by EGTA and the CaM- 
antagonist CGS 9343B. Phosphorylation of eEF-2 in murine pancreas 
cytosol was performed in the presence and absence (C, control) of 
5 x lO-3 M EGTA or various concentrations of CGS 9343B as de- 
scribed in section 2. The relative intensity of eEF-2 phosphorylation is 
given in percent of the control. 
an increase in the IC,, of rottlerin (Fig. 3). Recently, 
however, we had shown that rottlerin is able also to 
compete with ATP [23]. Therefore, it can be assumed 
that the suppression of eEF-2 kinase by rottlerin is a 
more complex process. The novel protein kinase inhibi- 
tor rottlerin might serve as a useful compound for the 
development of structurally related inhibitors with 
higher selectivity for eEF-2 kinase. 
Various protein kinase inhibitors, such as quercetin, 
phloretin, H-9, chelerythrin and genistein, were abso- 
lutely ineffective in suppressing eEF-2 phosphorylation 
up to a concentration of at least 10,~M (data not shown), 
with I& values > 100 ,LLM (Table 1). Within this group 
of inhibitors, quercetin was the most potent one. At 100 
,uM, it suppressed eEF-2 phosphorylation by 40%. Quer- 
cetin [24,25], phloretin [25], H-9 [26], and chelerythrin 
[27] are known to inhibit PKC with I&, values of 10 ,uM, 
20 ,uM, 18 ,uM and 0.66 ,uM, respectively. The flavonoid 
quercetin, however, is a rather unspecific inhibitor. The 
structurally related compound phloretin has not been 
tested for this so far. The isoquinoline sulfonamide H-9 
is not very specific either and inhibits several other pro- 
tein kinases, such as CAMP- and cGMP-dependent pro- 
tein kinases almost as effectively as PKC [26]. Genistein 
is known as an inhibitor of several but not all tyrosine 
kinases [29]. It suppresses PKC to some extent as well 
[301. 
In recent years, staurosporine was frequently used as 
the most potent inhibitor of PKC. Today, this inhibitor 
is well known to be rather unspecific, suppressing the 
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Fig. 2. Inhibition of eEF-2 phosphorylation by rottlerin (a) and stauro- 
sporine (b). The intensity of eEF-2 phosphorylation was determined by 
densitometric analysis of the autoradiograms (see inserts). 
activities of other protein kinases as effectively as PKC, 
i.e. in the nM range (Table 2). We were unable to confirm 
the extremely poor inhibition of PKCC by staurosporine 
reported by McGlynn et al. [35] and Kochs et al. [37]. In 
our hands PKCS is suppressed by staurosporine with an 
IC,, of 10-16 nM [23,28] comparable to the other PKC 
isoenzymes. In this respect, it was intriguing to observe 
that staurosporine up to a concentration of 50 ,uM did 
suppress eEF-2 kinase by less than 50% (Fig. 2b). A 
similar resistance to staurosporine was found only for 
casein kinase I and II. Staurosporine-related com- 
pounds, such as K252a or G66976, were similarly weak 
or even weaker inhibitors of eEF-2 kinase (data not 
Fig. 3. Effect of CaM on the inhibition of eEF-2 phosphorylation by 
rottlerin. 
shown). Previously, Go6976 was shown to exhibit a 
much higher specificity for PKC than staurosporine and 
even to be able to differentiate between Ca2’-responsive 
and Ca2+-unresponsive PKC isoenzymes [32,42]. Thus, 
eEF-2 kinase clearly represents an exception from the 
broad spectrum of protein kinase targets of stauro- 
sporine. This should be considered in studies in which 
staurosporine fails to suppress protein-kinase-mediated 
biological effects. 
Table 2 
Inhibition of protein kinases by staurosporine 
Protein kinase 1% (nM) Ref. 
cPKC WW 
PKCG 
PKCE 
PKC[ 
PKA 
PKG 
MAP-kinase 
S6-kinase 
cdc2-kinase 
MLCK 
CaM-kinase II 
Tyrosine kinases 
(PDGF-R, I-R, EGF-R, 
IGF-R, src) 
CKI 
CK II 
EF-2 kinase 
(CaM-kinase III) 
0.78-9 [28,31-341 
2-9; 500 [28,34,35] 
0.61-9 134,361 
l&16; 5,000-10,000 [23,28; 35: 
840 131,321 
18 [321 
I [331 
5 1381 
I [33,391 
10 1321 
40 WI 
&loo 
50,000 
15,000 
> 50,000 
[31,411 
[331 
[331 
see Fig. 2 
,371 
PKA, CAMP-dependent kinase; PKG, cGMP-dependent kinase; MAP- 
kinase, mitogen-activated protein kinase; MLCK, myosin light chain 
kinase; CK I and II, casein kinase I and II; R, growth factor receptor. 
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